Autoimmune inner ear disease.
The known etiologies of acquired sensorineural hearing loss include acoustic trauma, physical trauma, ototoxicity, genetic predisposition, infections, Meniere's disease, aging, and autoimmune disease. Treatments are directed at eliminating or managing the underlying disease process and aiding hearing with amplification. Rarely is it possible to improve unaided hearing after sensorineural loss except when the severe to profound level of loss is reached and cochlear implantation becomes an option. Autoimmune inner ear disease, however, is a treatable cause of sensorineural hearing loss and it is important for physicians and hearing health professionals to recognize that proper early diagnosis and management strategies may result in stabilization and possibly improvement in hearing.
Roland
J T
JT
Director Otology/Neurotology, New York University Medical Center, 530 First Avenue, Suite 3C, New York, NY 10016, USA. Tom.Roland@Med.Nyu.Edu
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000818:Animals; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000453:epidemiology / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007759:Labyrinth Diseases / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D010956:Plasmapheresis / Q000379:methods; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D003520:Cyclophosphamide; D008727:Methotrexate